Effect of Drug Efficacy and the Eclipse Phase of the Viral Life Cycle on Estimates of HIV Viral Dynamic Parameters
暂无分享,去创建一个
[1] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[2] Jaap Goudsmit,et al. Ongoing HIV dissemination during HAART , 1999, Nature Medicine.
[3] M. Lederman,et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. , 1999, The Journal of infectious diseases.
[4] D. Richman,et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.
[5] R. Siliciano,et al. Viral Dynamics in HIV-1 Infection , 1998, Cell.
[6] John L. Sullivan,et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.
[7] A. Perelson,et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.
[8] A. von Deimling,et al. Scientific Correspondence , 2011, Nature.
[9] L M Wahl,et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection , 1997, Journal of virology.
[10] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[11] C. A. Macken,et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.
[12] M A Nowak,et al. Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] Rob J. De Boer,et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.
[14] D. Volsky,et al. Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study. , 1991, The Journal of biological chemistry.
[15] A. Perelson,et al. A model of HIV-1 pathogenesis that includes an intracellular delay. , 2000, Mathematical biosciences.
[16] M A Nowak,et al. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[17] A A Ding,et al. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. , 1999, Mathematical biosciences.
[18] Lawrence M. Wein,et al. Mathematical considerations of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads , 1997 .
[19] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[20] D. Baltimore,et al. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression , 1989, Journal of virology.
[21] A S Perelson,et al. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Anderson,et al. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. , 1998, Journal of theoretical biology.
[23] N M Ferguson,et al. Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] L M Wahl,et al. Adherence and drug resistance: predictions for therapy outcome , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[25] L M Wahl,et al. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] V. Gruttola,et al. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? , 1999, AIDS.
[27] Sebastian Bonhoeffer,et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.
[28] Z. Grossman,et al. HIV infection: how effective is drug combination treatment? , 1998, Immunology today.
[29] D. Richman,et al. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells , 1990, Journal of virology.
[30] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.